Semax Peptide 2026: Evidence, FDA Review and What the Record Shows
Semax is a synthetic seven-residue peptide studied in small human experiments, neurological rehabilitation research and preclinical models. The July 2026 FDA advisory votes changed the public record. This guide separates the briefing, the vote, original studies, formulation limits and what remains unknown.
Current status — updated October 1, 2026. FDA staff’s May briefing weighed against adding Semax free base or Semax acetate to the 503A bulk list. On July 24, the advisory committee’s official result slides show separate votes of 8 yes, 5 no and 1 abstention for each form: free base at 7:52:32 and acetate at 8:04:36. The recommendations are advisory, not final FDA action.
Committee recommendation. A majority voted in favor of adding each Semax form to the list. The current 21 CFR 216.23 list, checked through September 30, 2026, does not include Semax free base or Semax acetate. For meeting context, see the full PCAC results.
The FDA 503A Review: What the July 24 Vote Did and Did Not Decide
The Pharmacy Compounding Advisory Committee met July 23–24, 2026 to discuss bulk drug substances proposed for the 503A framework. The May 11 FDA briefing is the agency’s evaluation document; the July 24 recording supplies the result slides. The free-base and acetate questions were separate, with one abstention on each slide. Together, these records distinguish staff analysis, the committee recommendation and any later final FDA action.
The 503A list is one regulatory mechanism, not a universal answer to whether a particular product can be prescribed, dispensed or used. FDA’s 503A overview distinguishes the codified list from conditional interim enforcement policy and other statutory requirements. A committee recommendation does not itself amend the list. For the other substances discussed at the meeting, see BPC-157, KPV, TB-500, and MOTS-c.
Both nomination packages were withdrawn, and FDA stated that it was evaluating the substances on its own initiative. Our full PCAC hearing guide covers the meeting context.
What FDA Reviewers Concluded
In the May 11 briefing, FDA staff wrote that, after considering the available information, a balancing of the criteria weighed against placing Semax free base or Semax acetate on the 503A bulk list. The review identified chemical-identity and quality-data gaps, limited evidence for the evaluated uses and insufficient information to characterize the safety profile. This is a staff recommendation for an advisory process, not a final agency decision.
The form distinction matters. Semax free base and Semax acetate are different active pharmaceutical ingredients, and references do not always state which form was studied. Findings need to be matched to the formulation and route actually tested.
The FDA briefing also discusses proposed nasal-spray and subcutaneous products. It highlights formulation, device, microbial-quality, impurity and route-specific questions that need to be kept separate from the molecule’s research record.
Nominated Uses, Evaluated Uses and List Scope
The briefing and its footnotes 3–4 evaluate cerebral ischemia, migraine and trigeminal neuralgia. Semax was also nominated for ADHD and “nootropic” use, but ADHD was not evaluated because supporting literature was not found, while “nootropic” was considered as part of the cerebral-ischemia evaluation.
Footnote 4 adds an important boundary: FDA evaluates a nominated bulk substance in the context of proposed compounded-drug uses, while acknowledging that inclusion on the 503A list may not be limited to a specific indication. That is a statement about possible list scope, not a promise that any particular route, patient, pharmacy or product is lawful. The current rule and any final FDA notice still control the question asked.
The nomination materials proposed both intranasal spray and subcutaneous injection. Route, salt or free-base form, concentration and device are part of the evidence question; they should not be collapsed into a single “Semax” pathway.
What Semax Is and How It Is Thought to Work
Semax is a synthetic heptapeptide with the sequence Met–Glu–His–Phe–Pro–Gly–Pro, described as an analogue of an ACTH(4–10) fragment. It is not the full ACTH hormone. The FDA briefing separately identifies free base and acetate forms.
Preclinical work provides a plausible mechanism, not a human treatment result. In a rat hippocampus study, a single Semax exposure was associated with increased BDNF protein, TrkB phosphorylation and related mRNA measures, alongside more conditioned-avoidance responses. See the Dolotov et al. rat study. Those measurements support a research hypothesis about BDNF/TrkB signaling; they do not establish a human cognitive dose, durable benefit or safety.
The human studies below examine different questions: task performance, post-stroke rehabilitation and functional brain connectivity.
The Human Evidence: Early Signals, Narrow Studies
The human record includes different populations and endpoints. In a small 1996 randomized, double-blind operator pilot, 16 healthy men were split into eight receiving Semax and eight receiving placebo. The Semax group received 1 mg intranasally on two workdays. The report described task-performance benefits, but spontaneous (false) responses also increased. Read the Kaplan et al. report as a short pilot, not a general regimen or long-term safety study.
Gusev et al. studied 110 adults after ischemic stroke in early or late rehabilitation. The authors reported random subgrouping and used 1% nasal drops at 6,000 mcg/day in two 10-day courses separated by 20 days. They reported higher plasma BDNF and improved Barthel functional recovery, while motor/paresis recovery was also related to rehabilitation timing. The original report does not describe placebo control or blinding; this is disease-context evidence, not a healthy cognitive cycle.
Panikratova et al. examined 52 healthy participants in separate Semax, Selank and placebo groups. The publisher abstract describes resting-state functional-connectivity measurements at baseline and 5 and 20 minutes after exposure. Separate arms are not a Semax-plus-Selank stack study, and an imaging endpoint is not demonstrated memory or attention improvement.
Across these studies, population, formulation, route, endpoint and follow-up differ. Positive signals are worth preserving, but they do not support a universal efficacy claim, fixed onset promise or broad superiority over approved or established alternatives.
Safety: Possible Risks, Uncertain Rates
The manufacturer-hosted 0.1% nasal-drop label reports possible mild nasal irritation with prolonged use and lists product-specific contraindications including pregnancy, lactation, acute mental states, disorders accompanied by anxiety and a history of seizures. Those directions belong to that liquid product; they do not validate an unidentified powder, spray or injection.
FDA’s briefing discusses a possible bleeding concern from limited literature and possible aggregation, impurity and immunogenicity concerns for injection. The document did not quantify a human event rate for those concerns and did not identify human subcutaneous pharmacokinetic or safety data. These remain formulation- and route-sensitive uncertainties.
Regulatory status and clinical evidence are separate questions. The exact active form, route, product quality and intended indication should be reviewed together.
Dosing: Where the Numbers Come From
The sources reviewed here do not establish a universal Semax dose for cognitive use. The operator pilot, post-stroke study and manufacturer label each describe different products, populations and purposes. Their exposures should not be merged into a single online range, repeat-dose schedule or prescription instruction.
For the evidence-separated discussion of nasal-drop label context, study exposures, subcutaneous evidence gaps, concentration math and timing, see our Semax dosage guide.
The nomination materials proposed both intranasal spray and subcutaneous injection. That fact describes the products under FDA review; it does not establish that nasal and subcutaneous delivery have equivalent absorption, device output, sterility or safety.
The Supply Problem
Regulatory status and product quality are separate questions. Research-channel listings labeled not for human consumption may not provide the identity, concentration, sterility, endotoxin, impurity or aggregation information needed to treat a product as a finished medicine. FDA evaluated submitted nomination materials, not a market-wide survey; its review identified inconsistent identity details in submitted certificates of analysis and the need to examine exact free-base or salt form, concentration, impurities, microbial quality, route-specific sterility and endotoxin, and device output.
A certificate, label or online listing is not by itself a validated clinical-quality assessment. For broader context, see our guides on peptide grey market risks, whether peptides are legal, and where to buy peptides. Storage also matters; see peptide storage.
Semax Compared to Selank and Other Nootropics
Selank is often discussed alongside Semax, but shared marketing language is not a combination study. The Panikratova experiment used separate Semax, Selank and placebo groups and measured connectivity, not a Semax-plus-Selank regimen. Our Semax vs Selank comparison can help compare their research populations and evidence limits.
A peptide label does not establish superiority over a small-molecule nootropic. Against Noopept, compare the actual study designs, endpoints, quality controls and regulatory status rather than assuming that one category is inherently safer or more effective.
Among other subjects discussed at the July meeting, DSIP (emideltide) and epitalon have their own evidence and regulatory records. Similar agenda placement does not make their findings interchangeable with Semax.
What to Watch After the Advisory Vote
The next meaningful evidence milestones are a dated final FDA action or list change, better-controlled human trials with clear form and route, and formulation-specific identity, quality, pharmacokinetic and safety data. Check the current eCFR provision and the applicable FDA notice before describing either form as listed, eligible or compoundable.
Keep the legal question separate from clinical appropriateness. For related regulatory context, see our FDA 503B GLP-1 exclusion guide and 14 peptides reclassification background.
Frequently Asked Questions About Semax
The July 24, 2026 Pharmacy Compounding Advisory Committee votes were not a ban or a final approval. The official result slides show separate 8-5 votes, with one abstention, for Semax free base and Semax acetate. FDA still has to make a final agency decision, and neither form appears in the current 21 CFR 216.23 list checked through September 30, 2026. Do not treat an advisory vote as an automatic legal pathway.
The May 11, 2026 FDA briefing said that the available information weighed against placing either Semax free base or Semax acetate on the 503A bulk list. The briefing discussed identity and quality gaps, limited effectiveness information for the evaluated uses and unresolved safety questions. That was staff analysis for an advisory process, not the final agency action; the later committee votes were separate advisory recommendations.
The briefing evaluated cerebral ischemia, migraine and trigeminal neuralgia. Its footnotes also say ADHD and nootropic uses were nominated but evaluated differently: ADHD lacked supporting literature in the review, while “nootropic” was considered in the cerebral-ischemia evaluation. The briefing cautions that inclusion on a 503A list may not be limited to a specific indication, so it is inaccurate to describe the vote as either a general nootropic approval or an indication-limited legal guarantee.
The briefing discusses a possible bleeding concern from limited literature and possible aggregation, impurity and immunogenicity concerns for injection. It did not quantify a human event rate for those concerns and did not identify human subcutaneous pharmacokinetic or safety data. The concerns are formulation- and route-sensitive evidence limitations, not proof that every Semax exposure causes harm.
The available record does not establish a molecule-wide safety conclusion. Human studies are small or indication-specific, many references do not clearly identify the active form, and long-term safety remains unresolved. The manufacturer-hosted Russian label has product-specific cautions, while the FDA briefing raises separate questions about proposed compounded forms. Neither reassurance from personal experience nor regulatory status alone settles safety.
There are limited positive signals, but they are not a general proof of durable cognitive enhancement. A small randomized double-blind operator pilot reported task-performance findings with increased spontaneous false responses, while a 2020 study measured resting-state connectivity in separate Semax, Selank and placebo groups. A rat study linked Semax exposure to hippocampal BDNF and TrkB changes and conditioned-avoidance behavior. These findings differ in population, endpoint and species and do not establish a universal human effect.
The sources do not establish one FDA-recognized dose or a universal route-specific schedule for cognitive use. The original human studies used study-specific intranasal exposures, and the post-stroke study used a disease-specific course that should not be converted into a nootropic cycle. Product concentration, device output, formulation, active form and clinical indication all matter. See the Semax dosage guide for the evidence-separated dosing discussion.
The vote remains advisory and non-binding. FDA may accept, modify or reject the committee recommendation; the record does not say when any rulemaking could be completed. The current codified 21 CFR 216.23 list checked through September 30, 2026 does not include Semax free base or Semax acetate. A future final action would need to be verified in the applicable FDA record rather than inferred from the meeting result.
Semax and Selank have different research emphases, but the 2020 imaging study used separate Semax, Selank and placebo groups rather than testing a Semax-plus-Selank stack. No source reviewed here establishes that a combination balances effects or adds a safety advantage. Compare their populations, endpoints and formulation limits instead of treating a shared marketing category as proof of combined benefit.
Availability and legal status are product- and jurisdiction-specific questions. Research-channel listings labeled not for human consumption do not by themselves establish identity, sterility, purity or a lawful clinical pathway. FDA’s briefing identified characterization and quality-control gaps for the evaluated bulk substances and proposed forms; that does not establish the quality of every listing, nor does a listing prove suitability. Verify the exact product and seek qualified clinical and pharmacy advice.